share_log

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

6-K:外國發行人報告
美股SEC公告 ·  2024/08/31 05:04

Moomoo AI 已提取核心訊息

NeuroSense Therapeutics has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive trading days. The company has been granted a grace period until February 24, 2025, to regain compliance by maintaining a closing bid price of $1.00 or above for at least 10 consecutive business days.The notification has no immediate impact on NeuroSense's Nasdaq listing or trading status, and shares will continue trading under the symbol "NRSN". If compliance is not achieved by the deadline, the company may be eligible for an additional 180-day extension, provided it meets other Nasdaq Capital Market listing requirements. The company's business operations remain unaffected by this notification.
NeuroSense Therapeutics has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its shares traded below $1.00 for 30 consecutive trading days. The company has been granted a grace period until February 24, 2025, to regain compliance by maintaining a closing bid price of $1.00 or above for at least 10 consecutive business days.The notification has no immediate impact on NeuroSense's Nasdaq listing or trading status, and shares will continue trading under the symbol "NRSN". If compliance is not achieved by the deadline, the company may be eligible for an additional 180-day extension, provided it meets other Nasdaq Capital Market listing requirements. The company's business operations remain unaffected by this notification.
NeuroSense Therapeutics 收到了納斯達克關於不符合最低買盤價格要求的通知,因爲其股票在連續 30 個交易日內交易價格低於 1.00 美元。該公司獲得了一個寬限期,直到 2025 年 2 月 24 日,以通過維持至少 10 個連續業務日的收盤買盤價在 1.00 美元或以上來恢復合規。該通知對 NeuroSense 的納斯達克上市或交易狀態沒有即時影響,股票將繼續在標的 "NRSN" 下交易。如果在截止日期之前未能達成合規,企業可能有資格獲得額外 180 天的延期,前提是滿足其他納斯達克資本市場上市要求。該公司的業務運營不受此通知的影響。
NeuroSense Therapeutics 收到了納斯達克關於不符合最低買盤價格要求的通知,因爲其股票在連續 30 個交易日內交易價格低於 1.00 美元。該公司獲得了一個寬限期,直到 2025 年 2 月 24 日,以通過維持至少 10 個連續業務日的收盤買盤價在 1.00 美元或以上來恢復合規。該通知對 NeuroSense 的納斯達克上市或交易狀態沒有即時影響,股票將繼續在標的 "NRSN" 下交易。如果在截止日期之前未能達成合規,企業可能有資格獲得額外 180 天的延期,前提是滿足其他納斯達克資本市場上市要求。該公司的業務運營不受此通知的影響。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息